Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
2 other identifiers
expanded_access
N/A
1 country
10
Brief Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 3, 2016
CompletedFirst Posted
Study publicly available on registry
June 7, 2016
CompletedOctober 31, 2017
October 1, 2017
June 3, 2016
October 27, 2017
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
- To fulfill the requirement of HR+ disease, a breast cancer must express, by immunohistochemistry, at least 1 of the hormone receptors (estrogen receptor or progesterone receptor).
- To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either immunohistochemistry or in-situ hybridization.
- Have recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy.
- Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group scale.
- Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving abemaciclib, and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia and peripheral neuropathy.
- Have adequate organ function, including:
- Hematologic: absolute neutrophil count ≥1.5 × 10⁹/Liter (L), platelets ≥100 × 10⁹/L, and hemoglobin ≥8 grams/deciliter. Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the treating physician. Initial treatment should not begin earlier than the day after the erythrocyte transfusion.
- Hepatic: bilirubin ≤1.5 × the upper limit of normal (ULN) and alanine aminotransferase ≤3 × ULN.
- Renal: serum creatinine ≤ULN.
- If a woman of child-bearing potential, must test negative for pregnancy at the time of enrollment based on serum pregnancy test, and must agree to use a reliable method of birth control during the program and for 3 months following the last dose of the abemaciclib.
- If a man, must agree to use a reliable method of birth control and to not donate sperm during the program and for at least 3 months following the last dose of abemaciclib (or country requirements, whichever is longer).
- Are able to swallow capsules.
You may not qualify if:
- Are currently enrolled in a clinical trial involving an investigational product or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this program.
- Have progressive central nervous system metastasis that require immediate local therapy including (but not limited to) whole-brain radiotherapy, stereotactic radiosurgery, surgical resection, or intrathecal chemotherapy.
- Have a history of progressive disease during prior therapy with a cyclin-dependent kinase (CDK) 4\&6 inhibitor.
- Have had major surgery within 14 days of the initial dose of abemaciclib.
- Have a personal history of any of the following conditions: syncope of either unexplained or cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest.
- Have active bacterial, fungal, and/or known viral infection.
- If lactating, must agree to not begin and/or discontinue breastfeeding.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Pacific Cancer Care
Monterey, California, 93940, United States
UCLA Medical Center
Santa Monica, California, 90404, United States
Orlando Health, Inc
Orlando, Florida, 32806, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
University of Minnesota Medical Center, Fairview Lakes
Wyoming, Minnesota, 55092, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
Memorial Sloan Kettering Cancer Center
Commack, New York, 11725, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, 75246, United States
West Virginia University Hospital
Morgantown, West Virginia, 26506, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Eli Lilly and Company
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 3, 2016
First Posted
June 7, 2016
Last Updated
October 31, 2017
Record last verified: 2017-10